Winner of the 2011 APEX Award for Publication Excellence follow @IntMedNews
RSS Feeds
Find Us on Facebook

American Heart Association's Scientific Sessions 2010

Eplerenone Reduced Mortality 24% in Mild Heart Failure

CHICAGO - Adding eplerenone to standard therapy significantly cut the risk of cardiovascular death and heart failure hospitalization by more than one-third in patients with mild heart failure in the phase III EMPHASIS-HF trial.

CRT Plus ICD Reduces Mortality in Mild Heart Failure

CHICAGO - For the first time, cardiac resynchronization therapy has been shown to offer a survival benefit beyond that provided by an implantable cardioverter defibrillator in patients with mild heart failure, a study has shown.

Video: New Options Prevent Complications in Atrial Fibrillation

CHICAGO - Dr. Gordon F. Tomaselli, chief of the Division of Cardiology at Johns Hopkins University School of Medicine, says that for the first time there are other options besides warfarin for treating patients at risk of thromboembolic complications of atrial fibrillation.

Omega-3 Fatty Acids Do Not Prevent Atrial Fibrillation Recurrence

Omega-3 polyunsaturated acid supplementation does not prevent recurrence of atrial fibrillation, according to a multisite, prospective, randomized trial presented by Dr. Peter R. Kowey of Lankenau Hospital.

Nesiritide Shown Safe for Acute Decompensated Heart Failure

CHICAGO - Five years of uncertainty about nesiritide’s safety for treating acute decompensated heart failure came to an end, as results from a multicenter trial with more than 7,000 patients proved the drug does no harm.

AED Use in Hospitals Reduces Survival by 15%

CHICAGO - Contrary to conventional wisdom, the use of automated external defibrillators for in-hospital cardiac arrests does not improve survival, a large national study shows.

Drug-Eluting Stents Safe as Bare-Metal in Large-Vessel Coronary Disease

CHICAGO - Drug-eluting stents are as safe as bare-mental stents when implanted in patients with large-vessel coronary artery disease, according to results of the BASKET-PROVE trial.

HDL Soars, LDL Drops With Novel CETP Inhibitor Anacetrapib

CHICAGO – The experimental oral agent anacetrapib increased HDL cholesterol levels by a staggering 138%, compared with placebo, in high-risk patients and did so without the negative side effects that plagued another drug in the same class.

Renal Denervation Slashed Blood Pressure in Drug-Resistant Hypertensives

CHICAGO – Deactivating the renal sympathetic nerves via a catheter-based procedure achieved impressively large and durable reductions in blood pressure in the first randomized, multicenter trial of the novel therapy in patients with resistant hypertension.

I would like to receive The IMpulse E-Newsletter each week.


Specialty Focus
Sponsored by
Adolescent Medicine
Cardiology
Dermatology
Diabetes, Endocrinology & Metabolism
Gastroenterology
Geriatric Medicine
Infectious Diseases
Mental Health
Nephrology & Urology
Neurology
Oncology & Hematology
Practice Trends
Pulmonary Disease & Sleep Medicine
Rheumatology & Immunology


calendar
May 11 - 21
Departs Civitavecchia, 		Rheumatology and Orthopaedics
May 11 - 21
Departs Civitavecchia, 		Rheumatology and Orthopaedics
May 12 - 21
Departs Oslo, 		Pain Management/Neurology/Compliance
May 18 - 23
San Francisco, CA		 American Thoracic Society (ATS): International Conference
May 19 - 22
New York, NY		 American Society of Hypertension (ASH): Annual Scientific Meeting
May 19 - 22
San Diego, CA		 Digestive Disease Week (DDW 2012)
May 19 - 22
Sao Paulo, 		XXX RADLA 2012: Annual Meeting of Latin American Dermatologists
May 19 - 24
Atlanta, GA		 American Urological Association (AUA): Annual Meeting
May 19 - 23
Stockholm, 		European Calcified Tissue Society (ECTS): Annual Congress
May 20 - 23
Brisbane, 		Australasian College of Dermatologists: Annual Scientific Meeting
More Calendar »